[ad_1]
US researchers have developed an experimental drug that potentially slows the progression of Parkinson's disease and its symptoms.
Researchers at the Johns Hopkins University of Maryland conducted experiments on human brain cell cultures and living murine models. reported that the drug blocked the degradation of brain cells that is the hallmark of Parkinson's disease.
"He is surprisingly protective of target nerve cells," said Ted Dawson, a professor at the University School of Medicine.
NLY01, is similar to compounds used to treat diabetes and is expected to undergo clinical trials this year.
If it's successful in humans, it could be one of the first treatments to directly target the progression of Parkinson's disease, not just the muscle. stiffness, spasmodic movements, fatigue, dizziness, dementia and other symptoms of the disease, Dawson said in the article published in the journal Nature Medicine
In a first l & 39; Dawson's team treated human microglia – a type of brain cell that sends signals across the central nervous system in response to infection or injury – with NLY01 and found that they were able to turn the signals of In addition, the researchers injected alpha-synuclein – the protein known to be the main driver of Parkinson's disease – in mice and mice treated with NLY01 retained their normal physical function and n & rdquo; Have not lost dopaminergic neurons, which indicates In another experiment, the team used mice that were genetically engineered to naturally produce more alpha-synuclein than typ The human body typically used to model Parkinson's disease in man who is prevalent in families
. ] Although under normal conditions, these so-called transgenic mice will succumb to the disease in 387 days, those treated with NLY01 have prolonged the life of more than 120 days
However, the experimental drug must still be tested for safety as well as efficiency in people, warned Dawson.
IANS
[ad_2]
Source link
